Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Taysha Gene Therapies (Nasdaq: TSHA) will report full-year 2025 financial results and host a corporate update conference call and webcast on Thursday, March 19, 2026 at 8:30 AM ET.
Taysha Gene Therapies (Nasdaq: TSHA) will report full-year 2025 financial results and host a corporate update conference call and webcast on Thursday, March 19, 2026 at 8:30 AM ET.
Investors can access the live webcast and later archived replay via the company’s Events and Presentations page at ir.tayshagtx.com for the company update and Q&A.
On Mar 12, the day this news came out, TSHA closed 2.10% above the previous close.
Data tracked by StockTitan Argus for the Mar 12 session.
Market Context
This announcement simply sets the timetable for TSHA’s full-year 2025 results and corporate update o...
Analysis
This announcement simply sets the timetable for TSHA’s full-year 2025 results and corporate update on March 19, without offering new financial or clinical metrics. Context from recent history matters: Q3 2025 featured $297.3M in cash with runway into 2028 and FDA Breakthrough Therapy designation for TSHA-102, while subsequent updates highlighted progress in the Rett pivotal program. Investors may focus on cash runway, R&D spending, and pivotal trial timelines when those full-year figures and commentary are released.
Key Figures
Cash balance:$297.3MR&D expense:$25.7MNet loss:$32.7M+5 more
Cash balance
$297.3M
Q3 2025 cash, runway into 2028
R&D expense
$25.7M
Q3 2025 research and development spend
Net loss
$32.7M
Q3 2025 quarterly net loss
REVEAL dose
1x10^15 vg
Single intrathecal dose in pivotal Rett trial
REVEAL sample size
15 females
Planned enrollment, ages 6 to <22 years
Interim analysis window
6 months
REVEAL interim analysis that may support BLA
Breakthrough Therapy
Designation granted
TSHA-102 for Rett syndrome, reported 2025-11-04
RTW ownership
8.3%
23,407,133 shares beneficially owned via SCHEDULE 13G/A
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adeno-associated virus, aav, central nervous system, cns, +3 more
7 terms
adeno-associated virusmedical
"advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic"
Adeno-associated virus (AAV) is a naturally occurring, small virus that researchers use as a safe carrier to deliver corrective genes into human cells, much like a specialized delivery van transporting instructions to a malfunctioning machine. It matters to investors because AAV-based therapies drive large development costs, unique manufacturing and regulatory risks, and the potential for high-value, one-time treatments that can significantly affect a biotech company’s future revenue and valuation.
aavmedical
"advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic"
AAV is a small, generally harmless virus repurposed by researchers as a delivery vehicle to insert therapeutic genes into human cells; think of it as a postal service that carries corrective DNA to specific tissues. Investors pay attention because AAV-based treatments can offer durable, potentially one-time cures that command high prices, but they also carry development, manufacturing and regulatory risks that can sharply influence a biotech company’s value.
central nervous systemmedical
"diseases of the central nervous system (CNS), today announced that it will report"
The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.
cnsmedical
"diseases of the central nervous system (CNS), today announced that it will report"
CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.
breakthrough therapy designationregulatory
"TSHA-102 received FDA Breakthrough Therapy designation for Rett syndrome and the"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
intrathecalmedical
"open-label study of a single intrathecal dose of 1x10^15 vg in 15 females"
Intrathecal describes a method of delivering a drug or therapy directly into the fluid-filled space around the spinal cord and brain so the medicine reaches the central nervous system more directly. For investors, intrathecal delivery matters because it often signals higher development complexity, specialized manufacturing and administration, and greater regulatory and safety scrutiny—factors that can affect costs, timelines and market adoption like choosing a specialist tool instead of a general one.
rule 144financial
"insider plans small stock sale under Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2025, and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time.
Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha’s website at ir.tayshagtx.com. An archived replay of the webcast will be available on the Company’s website.
About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.
Company Contact: Hayleigh Collins Senior Director, Corporate Communications and Investor Relations Taysha Gene Therapies, Inc. hcollins@tayshagtx.com
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Taysha (TSHA) release full-year 2025 financial results and hold the webcast?
Taysha will release full-year 2025 results and host a webcast on March 19, 2026 at 8:30 AM ET. According to the company, the live webcast will be available on its Events and Presentations page and an archived replay will be posted afterward.
How can investors access Taysha Gene Therapies (TSHA) live conference call and replay?
Investors can access the live conference call and replay via the company’s Events and Presentations page at ir.tayshagtx.com. According to the company, the webcast will stream live on March 19, 2026 with an archived replay available on the website afterward.
What time is Taysha’s (TSHA) corporate update call on March 19, 2026?
The corporate update call is scheduled for 8:30 AM Eastern Time on March 19, 2026. According to the company, the session will include a corporate update and Q&A and will be webcast live on the investor site with a replay posted later.
Will Taysha (TSHA) provide an archived replay of the March 19, 2026 webcast?
Yes, an archived replay will be available on the company website after the live event. According to the company, the webcast will be posted on its Events and Presentations page so investors can review the full corporate update and Q&A afterward.
What topics will Taysha (TSHA) likely cover in the March 19, 2026 corporate update webcast?
The webcast will cover the company’s full-year 2025 financial results and a corporate update on clinical progress and strategy. According to the company, the event will include management remarks and a Q&A session accessible via the live webcast and archived replay.
